Impairment of the insulinotropic effect of gastric inhibitory polypeptide (GIP) in obese and diabetic rats is related to the down-regulation of its pancreatic receptors

General Physiology and Biophysics

Volumn 26, Issue 3, 2007, Pages 181-193

  Younan, Sandra M ^a   Rashed, L A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

GIP receptors; Incretin; Obese rats; Type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCOSE; HORMONE RECEPTOR; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DOWN REGULATION; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE RELEASE; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT;

ANIMALS; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; MALE; OBESITY; PANCREAS; RATS; RECEPTORS, GASTROINTESTINAL HORMONE;

RATTUS;

EID: 36549062060     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Abrahamsen N., Lundgren K., Nishimura E. (1995): Regulation of glucagon receptor mRNA in cultured primary rat hepatocytes by glucose and cAMP. J. Biol. Chem. 270, 15853-15857
2. Ahren B., Larsson H., Holst J. J. (1997): Reduced gastric inhibitory polypeptide but normal glucagon-like peptide-1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur. J. Endocrinol. 137, 127-131
3. Bailey C. J., Flatt P. R., Kwasowski P., Powell C. J., Marks V. (1986): Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta. Endocrinol. 112, 224-229
4. Ballinger A. (2003): Gastric inhibitory polypeptide links overnutrition to obesity: a gut derived peptide, gastric inhibitory polypeptide, directly links overnutrition to obesity and may be a potential target for antiobesity drugs. Gut 52, 319- 320
5. Bruce D. G., Chisholm D. J., Storlien L. H., Kraegen E. W. (1988): Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 37, 736-744
6. Carlson O., Theodorakis M., Muller D. C., Egan J. M. (2004): Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 27, 1692-1698
7. Creutzfeldt W. (1979): The incretin concept today. Diabetologia 16, 75-85 (in German)
8. D'Alessio D. A. (1997): Peptide hormone regulation of islet cells. Horm. Metab. Res. 29, 297-300
9. Deacon C. F., Nauck M. A., Meier J., Holst J. J. (2000): Degradation of endogenous and exogenous gastric inhibitory peptide in healthy and type 2 diabetes subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 85, 357-368
10. Delams H. G. (1986): Biochemical analysis of human and animal serum for monoclonal antibodies using ELISA. Biochem. 14, 214-231
11. Ding W. G., Gromada J. (1997): Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta cells by glucose-dependent insulinotropic polypeptide. Diabetes 46, 615-621
12. Dobrian A. D., Michael J. D., Russell L. P. Thomas J. L. (2000): Development of hypertension in a rat model of diet-induced obesity. Hypertension 35, 1009-1019
13. Drucker D. J. (2003a): Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol. Endocrinol. 17, 161-171
14. Drucker D. J. (2003b): Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26, 2929-2940
15. Ehses J. A., Casilla V. R., Doty T., Pospisilik J. A., Winter K. D., Demuth H. U., Pederson R. A., McIntosh C. H. (2003a): Glucose-dependent insulinotropic polypeptide promotes β-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144, 4433-4445
16. Ehses J. A., Lee S. S., Pederson R. A., McIntosh C. H. (2003b): A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling: evidence for the involvement of phospholipase A2 in GIP-stimulated insulin secretion. J. Biol. Chem. 276, 23667-23673
17. Ehses J. A., Pelech S. L, Pederson R. A., McIntosh C. H. (2003c): Glucose-dependent insulinotropic polypeptide (GIP) activates the Raf-Mek 1/2-ERK 1/2 module via a cyclic AMP/PKA/Rap1-mediated pathway. J. Biol. Chem. 277, 37088-37097
18. Elahi D., McAloon-Dyke. M., Fukagawa N. K., Meneilly G. S., Sclater A. L., Minaker K. L., Habener J. F., Andersen D. K. (1994): The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regu]. Pept. 51, 63-74
19. Fehmann H., Goke R., Goke B. (1995): Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing po]ypeptide. Endocr. Rev. 16, 390-410
20. Freeman W. M., Walker S. J., Vrana K. F. (1999): Quantitative RTPCR: pitfalls and potential. Biotechniques 26, 112-125
21. Fukase N., Igarashi M., Takahashi H., Manaka H., Yamatani K., Daimon M., Tominaga M. Sasaki H. (1993): Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet. Med. 10, 44-49
22. Gault V. A., Flatt P. R., O'Harte F. P. (2003): Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem. Biophys. Res. Commun. 308, 207-213
23. Hinke S. A., Pauly R. P., Ehses J., Kerridge P., Demuth H. U., McIntosh C. H., Pederson R. A. (2000): Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (βTC-3) cells to glucose-dependent insulinotropic polypeptide. J. Endocrinol. 165, 281-291
24. Holst J. J. Gromada J. (2004): Role of incretin hormones in the regulation of insulin secretion in diabetic and non-diabetic humans. Am. J. Physiol., Endocrinol. Metab. 287, E199-206
25. Holst J. J., Gromada J., Nauck M. A. (1997): The pathogenesis of NIDDM involves a defective expression ofthe GIP receptor. Diabetologia 40, 984-986 (in German)
26. Holz G. G. (2004): Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic β-cell. Diabetes 53, 5-13
27. Juan C. C., Shen Y. W., Chien Y., Lin Y. J., Chang S. F., Ho L. T. (2004): Insulin infusion induces endothelin-1-dependent hypertension in rats. Am. J. Physiol., Endocrinol. Metab. 287, E948-954
28. Knapper J. M., Puddicombe S. M., Morgan L. M., Fletcher J. M. (1995): Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon like peptide-1 (7-36) amide on lipoprotein lipase activity in explants of rat adipose tissue. J. Nutr. 125, 183-188
29. Kok N. N., Morgan L. M., Williams C. M., Roberfroid M. B., Thissen J. P., Delzenne N. M. (1998): Insulin, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and insulin-like growth factor I as putative mediators of the hypolipidemic effect of oligofructose in rats. J. Nutr. 128, 1099-1103
30. Lewis J. T., Dayanandan B., Habener J. F., Kieffer T. J. (2000): Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist. Endocrinology 141, 3710-3716
31. Livak M. F., Egan J. M. (2002): Glucose causes desensitization of isolated rat islets to glucose-dependent insulinotropic peptide. Diabetes 51 (Suppl. 2), 341
32. Lynn F. C., Pamir N., Ng E. H., McIntosh C. H., Kieffer T. J., Pederson R. A. (2001): Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50, 1004-1011
33. Mathews D. R., Hosker J. P., Rudenski A. S., Naylor B. A., Treacher D. F., Turner R. C. (1985): Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (in German)
34. Matz J. M., Lavio K. P., Epstein P. N., Blake M. J. (1996): Thermoregulatory and heat shock protein response deficits in cold-exposed diabetic mice. Am. J. Physiol. 270, R525-532
35. Meier J. J., Hucking K., Holst J. J., Deacon C. F., Schmiegel W. H., Nauck M. A. (2001): Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50, 2497-2504
36. Meier J. J., Nauck M. A., Schmidt W. E., Gallwitz B. (2002): Gastric inhibitory polypeptide: the neglected incretin revisited. Regul. Pept. 107, 1-13
37. Meier J. J., Holst J. J., Gallwitz B., Deacon C. F., Schmidt W. E., Nauck M. A. (2003): Gastric inhibitory polypeptide (GIP) dose dependently stimulates glucagons secretion in healthy human subjects at euglycemia. Diabetologia 46, 798-801 (in German)
38. Mitrakou A., Kelley D., Mokan M., Veneman T., Pangburn T., Reilly J., Gerich J. (1992): Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl. J. Med. 326, 22-29
39. Miyawaki K., Yamada Y., Yano H., Niwa H., Ban N., Ihara Y., Kubota A., Fujimoto S., Kajikawa M., Kuroe A., Tsuda K., Hashimoto H., Yamashita T., Tashiro F., Miyazaki J. I., Seino Y. (1999): Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 96, 14843-14847
40. Miyawaki K., Yamada Y., Ban N., Ihara Y., Tsukiyama K., Zhou H., Fujimoto S., Oku A., Tsuda K., Toyokuni S., Hiai H., Mizunoya W., Fushiki T., Holst J. J., Makino M., Tashita A., Kobara Y., Tsubamoto Y., Jinnouchi T., Jomori T., Seino Y. (2002): Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8, 738-742
41. Norušiš M. J. (1997): SPSS 7.5 Guide to Data Analysis. Simon and Schuster Company, Upper Saddle River, New Jersey
42. Pamir N., Lynn F.C, Buchan A. M, Ehses J., Hinke S. A, Pospisilik J. A, Miyawaki K., Yamada Y., Seino Y., McIntosh C. H., Pederson R. A. (2003): Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am. J. Physiol., Endocrinol. Metab. 284, E931-939
43. Ramshur E. B., Rull T. R., Wice B. M. (2002): Novel insulin/ GIP-producing cell lines provide unexpected insights into gut K-cell function in vivo. J. Cell. Physiol. 192, 339-350
44. Rorsman P., Eliasson E., Renstr E., Gromada J., Barg S., Sven P. (2000): The cell physiology of biphasic insulin secretion. News Physiol. Sci. 15, 72-77
45. Thompson S. A., Lynn F. C., Pospisilik J. A., Ehses J. A., Hinke S. A., Pamir N., McIntosh C. H., Pederson R. A. (2003): A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in β-cells. FASEB J. 17, 91-93
46. Trinder L. (1969): Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromagen. Ann. Clin. Biochem. 1, 24-29
47. Trumper A., Trumper K., Trusheim H., Arnold R., Goke B., Horsch D. (2001): Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 15, 1559-1570
48. Vilsboll T., Krarup T., Madsbad S., Holst J. J. (2002): Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45, 1111-1119 (in German)
49. Vilsboll T., Krarup T., Madsbad S., Holst J. J. (2003): Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 114, 115-121
50. Walsh J. H. (1994): Gastrointestinal hormones. In: Physiology of the Gastrointestinal Tract (Ed. L. R. Johnson), pp. 1-128, Raven, New York
51. ATP channel independent. Am. J. Physiol., Endocrinol. Metab. 284, E988-1000
52. Wang Y., Montrose-Rafizadeh C., Adams L., Raygada M., Nadiv O., Egan J. M. (1996): GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells. Mol. Cell. Endocrinol. 116, 81-87
53. Wheeler M. B., Gelling R. W., McIntosh C. H., Georgiou J., Brown J. C., Pederson R. A. (1995): Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 136, 4629-4639
54. Whittington K. B., Solomon S. S., Lu Z. N., Selawry H. P. (1991): Islet allografts in the cryptorchid testes of spontaneously diabetic BB/Wor dp rats: response to glucose, glipizide, and arginine. Endocrinology 128, 2671-2677